These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30323997)

  • 1. Once-Daily Cyclosporine-A-MiDROPS for Treatment of Dry Eye Disease.
    Coursey TG; Wassel RA; Quiambao AB; Farjo RA
    Transl Vis Sci Technol; 2018 Sep; 7(5):24. PubMed ID: 30323997
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
    Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
    Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ocular Distribution of Cyclosporine Following Topical Administration of OTX-101 in New Zealand White Rabbits.
    Weiss SL; Kramer WG
    J Ocul Pharmacol Ther; 2019 Sep; 35(7):395-402. PubMed ID: 31355703
    [No Abstract]   [Full Text] [Related]  

  • 4. Cyclosporine Amicellar delivery system for dry eyes.
    Kang H; Cha KH; Cho W; Park J; Park HJ; Sun BK; Hyun SM; Hwang SJ
    Int J Nanomedicine; 2016; 11():2921-33. PubMed ID: 27382280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Treatment Effect and Tolerance of the Topical Application of Mizoribine and Cyclosporine A in a Mouse Dry Eye Model.
    Lin X; Wu Y; Tang L; Ouyang W; Yang Y; Liu Z; Wu J; Zheng X; Huang C; Zhou Y; Zhang X; Chen Y; Li W; Hu J; Liu Z
    Transl Vis Sci Technol; 2020 Dec; 9(13):22. PubMed ID: 33364077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of cyclosporine A in ocular tissues after topical administration of cyclosporine A cationic emulsions to pigmented rabbits.
    Daull P; Lallemand F; Philips B; Lambert G; Buggage R; Garrigue JS
    Cornea; 2013 Mar; 32(3):345-54. PubMed ID: 23023401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca.
    Strong B; Farley W; Stern ME; Pflugfelder SC
    Cornea; 2005 Jan; 24(1):80-5. PubMed ID: 15604871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A semifluorinated alkane (F4H5) as novel carrier for cyclosporine A: a promising therapeutic and prophylactic option for topical treatment of dry eye.
    Gehlsen U; Braun T; Notara M; Krösser S; Steven P
    Graefes Arch Clin Exp Ophthalmol; 2017 Apr; 255(4):767-775. PubMed ID: 28091781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclosporine A eyedrops with self-nanoemulsifying drug delivery systems have improved physicochemical properties and efficacy against dry eye disease in a murine dry eye model.
    Bang SP; Yeon CY; Adhikari N; Neupane S; Kim H; Lee DC; Son MJ; Lee HG; Kim JY; Jun JH
    PLoS One; 2019; 14(11):e0224805. PubMed ID: 31738791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine inhibits apoptosis in experimental murine xerophthalamia conjunctival epithelium.
    Sun J; Wang J
    J Huazhong Univ Sci Technolog Med Sci; 2006; 26(4):469-71. PubMed ID: 17120751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Efficiency of Cyclosporine A-Eluting Contact Lenses for the Treatment of Dry Eye.
    Choi JH; Li Y; Jin R; Shrestha T; Choi JS; Lee WJ; Moon MJ; Ju HT; Choi W; Yoon KC
    Curr Eye Res; 2019 May; 44(5):486-496. PubMed ID: 30580651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease.
    Burade V; Zalawadia R; Patel A; Ogundele A
    Clin Ophthalmol; 2020; 14():2747-2755. PubMed ID: 33061257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ocular safety of cationic emulsion of cyclosporine in an in vitro corneal wound-healing model and an acute in vivo rabbit model.
    Liang H; Baudouin C; Daull P; Garrigue JS; Brignole-Baudouin F
    Mol Vis; 2012; 18():2195-204. PubMed ID: 22919267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, Safety, and Tolerability of a Novel Cyclosporine, a Formulation for Dry Eye Disease: A Multicenter Phase II Clinical Study.
    Peng WY; Chen RX; Dai H; Zhu L; Li Y; Gao ZQ; Li XY; Zhou SY
    Clin Ther; 2021 Mar; 43(3):613-628. PubMed ID: 33546885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Novel Eyes Topical Drug Delivery System: CsA-LNC for the Treatment of DED.
    Zhang A; Sun R; Ran M; Deng Y; Ge Y; Zhu Y; Tao X; Shang L; Gou J; He H; Yin T; Wang Y; Zhang Y; Tang X
    Pharm Res; 2020 Jul; 37(7):146. PubMed ID: 32666340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel micelle carriers for cyclosporin A topical ocular delivery: in vivo cornea penetration, ocular distribution and efficacy studies.
    Di Tommaso C; Bourges JL; Valamanesh F; Trubitsyn G; Torriglia A; Jeanny JC; Behar-Cohen F; Gurny R; Möller M
    Eur J Pharm Biopharm; 2012 Jun; 81(2):257-64. PubMed ID: 22445900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo characterisation of a novel water-soluble Cyclosporine A prodrug for the treatment of dry eye disease.
    Rodriguez-Aller M; Kaufmann B; Guillarme D; Stella C; Furrer P; Rudaz S; El Zaoui I; Valamanesh F; Di Tommaso C; Behar-Cohen F; Veuthey JL; Gurny R
    Eur J Pharm Biopharm; 2012 Apr; 80(3):544-52. PubMed ID: 22155591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Semifluorinated alkanes as a liquid drug carrier system for topical ocular drug delivery.
    Dutescu RM; Panfil C; Merkel OM; Schrage N
    Eur J Pharm Biopharm; 2014 Sep; 88(1):123-8. PubMed ID: 24844949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops.
    Daull P; Barabino S; Feraille L; Kessal K; Docquier M; Parsadaniantz SM; Baudouin C; Garrigue JS
    Curr Eye Res; 2019 May; 44(5):476-485. PubMed ID: 30664361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
    Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
    Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.